Mycoplasma Clearance and Risk Analysis in a Model Bioprocess

References

1. 1.↵
   1. Krieg N. R.,
   2. Holt J. G.

   1. Razin S.,
   2. Freundt E.

   , The Mycoplasmas. In Bergey's Manual of Systematic Bacteriology, 1 ed.; Krieg N. R., Holt J. G., Eds. Williams & Wilkins: Baltimore, 1984; Vol. 1, pp 740–770.

   OpenUrl
2. 2.↵
   1. Razin S.,
   2. Hayflick L.

   , Highlights of mycoplasma research–an historical perspective. Biologicals 2010, 38 (2), 183–190.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Hay R. J.

   , Operator-induced contamination in cell culture systems. Dev Biol Stand 1991, 75, 193–204.

   OpenUrlPubMed
4. 4.↵
   1. Ill C. R.,
   2. Dehghani H.

   , Risk reduction in biotherapeutic products. Curr Opin Drug Discov Devel 2009, 12 (2), 296–304.

   OpenUrlPubMed
5. 5.↵
   ICH Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products Q5D; International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use: Geneva, Switzerland, 1997.
6. 6.↵
   ICH Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products Q6B; International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use: Geneva, Switzerland, 1999.
7. 7.↵
   FDA Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals; Food and Drug Administration Rockville, MD, 1993.
8. 8.↵
   FDA Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications; Food and Drug Administartion Rockville, MD, 2010.
9. 9.↵
   1. Eldering J. A.,
   2. Felten C.,
   3. Veilleux C. A.,
   4. Potts B. J.

   , Development of a PCR method for mycoplasma testing of Chinese hamster ovary cell cultures used in the manufacture of recombinant therapeutic proteins. Biologicals 2004, 32 (4), 183–193.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Deutschmann S. M.,
    2. Kavermann H.,
    3. Knack Y.

    , Validation of a NAT-based Mycoplasma assay according European Pharmacopoiea. Biologicals 2010, 38 (2), 238–248.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Asarnow D.,
    2. Warford A.,
    3. Fernandez L.,
    4. Hom J.,
    5. Sandhu G.,
    6. Candichoy Z.,
    7. Luna G.,
    8. Goldman M.,
    9. Rarich R.

    , Validation and international regulatory experience for a mycoplasma touchdown PCR assay. Biologicals 2010, 38 (2), 224–231.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Zhi Y.,
    2. Mayhew A.,
    3. Seng N.,
    4. Takle G. B.

    , Validation of a PCR method for the detection of mycoplasmas according to European Pharmacopoeia section 2.6.7. Biologicals 2010, 38 (2), 232–237.

    OpenUrlCrossRefPubMed
13. 13.↵
    Council of Europe, Chapter 2.6.7. Mycoplasmas. In European Pharmacopoeia, 6 ed.; Strasbourg, France, 2007; pp 149–152.
14. 14.↵
    Pharmaceuticals and Medical Devices Agency. Chapter 14: Mycoplasma Testing for Cell Substrates used for the Production of Biotechnological/Biological Products. In Japanese Pharmacopoeia, 15 ed.; Tokyo, Japan, 2006; pp 1721–1724.
15. 15.↵
    1. Kondragunta B.,
    2. Drew J. L.,
    3. Brorson K. A.,
    4. Moreira A. R.,
    5. Rao G.

    , Advances in Clone Selection Using High-Throughput Bioreactors. Biotechnology Progress 2010, 26 (4), 1095–1103.

    OpenUrlPubMed
16. 16.↵
    1. Dabrazhynetskaya A.,
    2. Volokhov D. V.,
    3. David S. W.,
    4. Ikonomi P.,
    5. Brewer A.,
    6. Chang A.,
    7. Chizhikov V.

    , Preparation of reference strains for validation and comparison of mycoplasma testing methods. J Appl Microbiol 2011, 111 (4), 904–914.

    OpenUrlPubMed
17. 17.↵
    1. David S. A.,
    2. Volokhov D. V.,
    3. Ye Z.,
    4. Chizhikov V.

    , Evaluation of Mycoplasma inactivation during production of biologics: egg-based viral vaccines as a model. Appl Environ Microbiol 2010, 76 (9), 2718–2728.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    ICH Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin Q5A; International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use: Geneva, Switzerland, 1997.
19. 19.↵
    1. Farshid M.,
    2. Taffs R. E.,
    3. Scott D.,
    4. Asher D. M.,
    5. Brorson K.

    , The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals. Curr Opin Biotechnol 2005, 16 (5), 561–567.

    OpenUrlPubMed
20. 20.↵
    1. Laborde S.,
    2. Degrave A.,
    3. Lehmann D.,
    4. Jouette S.,
    5. Rofel C.,
    6. Muller T.,
    7. Hertzog N.,
    8. Rook M.,
    9. Ribault S.

    , Detection of Mollicutes in bioreactor samples by real-time transcription-mediated amplification. Lett Appl Microbiol 2010, 50 (6), 633–638.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Windsor H. M.,
    2. Windsor G. D.,
    3. Noordergraaf J. H.

    , The growth and long term survival of Acholeplasma laidlawii in media products used in biopharmaceutical manufacturing. Biologicals 2010, 38 (2), 204–210.

    OpenUrlPubMed
22. 22.↵
    1. Armstrong S. E.,
    2. Mariano J. A.,
    3. Lundin D. J.

    , The scope of mycoplasma contamination within the biopharmaceutical industry. Biologicals 2010, 38 (2), 211–213.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Dabrazhynetskaya A.,
    2. Furtak V.,
    3. Volokhov D.,
    4. Beck B.,
    5. Chizhikov V.

    , Preparation of reference stocks suitable for evaluation of alternative NAT-based mycoplasma detection methods. J Appl Microbiol 2014, 116 (1), 100–108.

    OpenUrl
24. 24.↵
    1. Rubinstein L. J.,
    2. Stein K. E.

    , Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. II. Specificity. J Immunol 1988, 141 (12), 4357–4362.

    OpenUrlAbstract
25. 25.↵
    1. Agarabi C. D.,
    2. Schiel J. E.,
    3. Lute S. C.,
    4. Chavez B. K.,
    5. Boyne M. T. 2nd.,
    6. Brorson K. A.,
    7. Khan M. A.,
    8. Read E. K.

    , Bioreactor process parameter screening utilizing a Plackett-Burman design for a model monoclonal antibody. J Pharm Sci 2015, 104 (6), 1919–1928.

    OpenUrl
26. 26.↵
    1. Piet M. P.,
    2. Chin S.,
    3. Prince A. M.,
    4. Brotman B.,
    5. Cundell A. M.,
    6. Horowitz B.

    , The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion 1990, 30 (7), 591–598.

    OpenUrl
27. 27.↵
    1. Miesegaes G.,
    2. Bailey M.,
    3. Willkommen H.,
    4. Chen Q.,
    5. Roush D.,
    6. Blumel J.,
    7. Brorson K.

    , Proceedings of the 2009 Viral Clearance Symposium. Dev Biol (Basel) 2010, 133, 3–101.

    OpenUrlPubMed
28. 28.↵
    1. Rogers M.,
    2. Hiraoka-Sutow M.,
    3. Mak P.,
    4. Mann F.,
    5. Lebreton B.

    , Development of a rapid sanitization solution for silica-based protein A affinity adsorbents. J Chromatogr A 2009, 1216 (21), 4589–4596.

    OpenUrlPubMed
29. 29.↵
    G. E. LifeSciences, Use of sodium hydroxide for cleaning and sanitization of chromatography media and systems. In Application note 18-1124-57 AI, 2014.
30. 30.↵
    1. Miesegaes G.,
    2. Lute S.,
    3. Brorson K.

    , Analysis of viral clearance unit operations for monoclonal antibodies. Biotechnol Bioeng 2010, 106 (2), 238–246.

    OpenUrlPubMed
31. 31.↵
    1. Horowitz B.,
    2. Bonomo R.,
    3. Prince A. M.,
    4. Chin S. N.,
    5. Brotman B.,
    6. Shulman R. W.

    , Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992, 79 (3), 826–831.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Milne C.,
    2. Daas A.

    , Establishment of European pharmacopoeia Mycoplasma reference strains. Pharmeuropa Bio 2006, 2006 (1), 57–72.

    OpenUrlPubMed
33. 33.↵
    1. Nubling C. M.,
    2. Baylis S. A.,
    3. Hanschmann K. M.,
    4. Montag-Lessing T.,
    5. Chudy M.,
    6. Kress J.,
    7. Ulrych U.,
    8. Czurda S.,
    9. Rosengarten R.,
    10. Mycoplasma G.

    Collaborative Study, World Health Organization International Standard To Harmonize Assays for Detection of Mycoplasma DNA. Appl Environ Microbiol 2015, 81 (17), 5694–5702.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    1. Dabrazhynetskaya A.,
    2. Volokhov D. V.,
    3. Lin T. L.,
    4. Beck B.,
    5. Gupta R. K.,
    6. Chizhikov V.

    , Collaborative study report: evaluation of the ATCC experimental mycoplasma reference strains panel prepared for comparison of NAT-based and conventional mycoplasma detection methods. Biologicals 2013, 41 (6), 377–83.

    OpenUrlCrossRefPubMed
35. 35.↵
    ASTM, E2888-12: Standard Practice for Process for Inactivation of Rodent Retrovirus by pH. ASTM International: Conshoken, PA, 2012.